Tag
Pharma / Healthcare
76 articles
Pharmaceutical companies are actively holding annual general meetings, approving financial statements, re-appointing directors, and addressing corporate governance matters. Several companies, including Alpa Laboratories, Innova Captab, and Syncom Formulations, reported unanimous approval of resolutions, highlighting shareholder confidence. Godavari Biorefineries secured a Mexican patent for antiviral compounds, while Zydus Lifesciences extended a joint venture investment deadline. However, Gujarat Themis Biosyn faced rejection of a resolution concerning promoter loans, indicating potential investor concerns regarding financial leverage. These developments underscore ongoing activity within the sector, with patent protection and corporate governance remaining key focal points for investors.
Alpa Laboratories 38th AGM Voting Results
Alpa Laboratories held its 38th Annual General Meeting virtually on September 30, 2026, with all seven proposed resolutions approved by shareholders.
Total shareholder participation was 49 members hol
Innova Captab 22nd AGM Approves All 10 Resolutions
Innova Captab Limited held its 22nd Annual General Meeting (AGM) on 30th September 2026 via video conferencing.
Shareholders approved all 10 resolutions, including adoption of financial statements and
Godavari Biorefineries Granted Mexican Patent for Antiviral Compounds
Godavari Biorefineries disclosed receipt of Mexican Patent No. 438818 for compounds treating viral infections.
The patent covers use of compounds inhibiting V-ATPase activity for manufacturing antivir
Zydus Lifesciences Extends JV Investment Deadline to December 2026
Zydus Lifesciences provides regulatory update on its 50% equity investment in Zydus Sunshine Lifesciences joint venture.
Company and partner Sunshine Healthcare extend transaction completion deadline
Ichor Biologics Writ Dismissed Over License Approval
Ichor Biologics challenged rejection of its technical bid in a West Bengal e‑tender for surplus Fresh Frozen Plasma, filing W.P.A. No.20748/2026.
The High Court held the renewal licence submitted lack
Supreme Court Dismisses SLP vs Styrax
The Supreme Court heard Special Leave Petitions filed by Union of India challenging High Court judgments dated 19‑02‑2026.
The petitions sought condonation of delay in filing and refiling the SLP agai
Syncom Formulations Approves 10% Final Dividend
Syncom Formulations shareholders approved a final dividend of ₹0.10 per share for FY 2025-26 at the 38th AGM.
The dividend will be paid to shareholders on record as of 23rd September 2026.
Payment wil
Syncom Formulations 38th AGM Voting Results Declaration
Syncom Formulations declared results for its 38th AGM held on September 30, 2026, via video conferencing, complying with SEBI LODR Regulation 44.
All 10 proposed resolutions were passed, including ado
Bliss GVS Pharma Board Approves Two ESOP Schemes
Board approved Senior Executive ESOP 2026 for up to 2.49% of equity shares (26.5 lakh shares).
Board approved Employee ESOP 2026 for up to 4.42% of equity shares (47 lakh shares).
Both schemes feature
Piramal Pharma Clarifies Ontario $1.7M Facility Funding
Piramal Pharma clarifies a news item regarding a $1.7M investment from the Ontario government for its Aurora facility upgrades.
The funding is for infrastructure, operational efficiency, and sustainab
Sun Pharma Seeks Shareholder Approvals for ESOP and Acquisition
Sun Pharma proposes new ESOP 2026 plan for up to 12 million options using secondary market shares without dilution.
Company seeks enhanced borrowing limit of ₹700 billion and investment limit of ₹800
Sun Pharma Presents LEQSELVI Two-Year Alopecia Data
Sun Pharma filed regulatory disclosure for LEQSELVI (deuruxolitinib) two-year clinical data presentation at EADV Congress 2026.
Open-label extension study showed sustained efficacy with 93.9% of Week
Sai Parenterals Schedules Analyst/Investor Meetings
Sai Parenterals intimates BSE and NSE of scheduled analyst and institutional investor meetings at its Hyderabad facilities.
Discussions will be based solely on publicly available information, with no
Fermenta Biotech Intimates October 7 Investor Meeting
Fermenta Biotech intimates a scheduled one-to-one physical investor meeting in Mumbai on October 7, 2026.
The disclosure is a regulatory filing pursuant to SEBI LODR Regulation 30 for investor relatio
Jagsonpal Acquires Group Pharma Wellness Portfolio
Jagsonpal Pharmaceuticals completed the acquisition of Group Pharmaceuticals' wellness portfolio for an upfront consideration of ₹23.7 crore.
The acquisition adds two key wellness brands and expands t
Lasa Supergenerics 11th AGM All Resolutions Approved
Lasa Supergenerics held its 11th AGM on September 30, 2026, with all seven proposed resolutions approved by shareholders with over 99.99% votes in favor.
The scrutinizer's report confirms compliance w
Beta Drugs Ltd 21st AGM Unanimous Voting Results
Beta Drugs Ltd submitted voting results for its 21st AGM held on September 30, 2026, pursuant to SEBI LODR Regulation 44.
All six proposed resolutions were passed unanimously with 100% shareholder app
Orchid Pharma 33rd AGM Voting Results Approval
Orchid Pharma Limited disclosed scrutinizer's report and voting results for its 33rd Annual General Meeting held via video conference on September 29, 2026.
All five resolutions were approved includin
Themis Medicare 56th AGM Voting Results Unanimous Approval
Themis Medicare Ltd. disclosed scrutinizer's report and voting results from its 56th AGM held on September 30, 2026.
All five resolutions were passed with overwhelming majority, including financial st
Gujarat Themis Biosyn 45th AGM Voting Results
Gujarat Themis Biosyn disclosed scrutinizer report and voting results for its 45th AGM held on September 30, 2026.
Shareholders approved eight resolutions including dividend declaration, director reap
Aurobindo Pharma Subsidiary A1 Labs Allots 20% Stake
Aurobindo Pharma's subsidiary Apitoria completed the allotment of a 20% stake in A1 Biochem Labs to its former promoter Dr. Rajendra Gadikota.
The transaction involved an infusion of ₹33.80 crore into
Lupin's Philippines Subsidiary Completes Full Buyback
Lupin discloses completion of buyback by Philippine subsidiary Multicare Pharmaceuticals Philippines, Inc. under SEBI Regulation 30.
MPPI bought back remaining 30,559 shares, achieving 100% ownership
Life Vision Healthcare SLP Filed, Notice Ordered
Supreme Court logged SLP (Criminal) No.17925/2026 filed by M/S Life Vision Healthcare & Anr. challenging a May 2026 High Court judgment.
The Court also heard IA No.287515/2026 and IA No.287516/2026 on
Aurobindo's Acrotech Launches ADQUEY Dermatology Drug in US
Acrotech Biopharma launches ADQUEY™, a novel topical PDE4 inhibitor for atopic dermatitis in US markets.
The product enters a US$1.3 billion market and marks Acrotech's entry into US dermatology thera
Arvee Laboratories 2026 AGM Voting Results
Arvee Laboratories submitted AGM voting results for four resolutions passed unanimously on September 29, 2026.
All resolutions received 100% favorable votes from 11,887,858 shares cast, representing f
Symbiotec Subsidiary Knovea Signs US DCV Agreement
Symbiotec's subsidiary Knovea Pharmaceutical enters exclusive US commercialization agreement for Dual Chamber Vial products with global pharma company.
Agreement covers two DCV-based injectable produc
Jeena Sikho Lifecare 9th AGM Voting Results
Jeena Sikho Lifecare held its 9th AGM on 28th September 2026, passing 15 resolutions including financial statements adoption and director appointments.
Shareholders approved a final dividend of ₹4.50
Dishman Carbogen Amcis 19th AGM Proceedings September 2026
Dishman Carbogen Amcis held its 19th AGM on 30th September 2026 via video conference, lasting 35 minutes.
Members passed four resolutions including adoption of FY26 financial statements and auditor re
Gujarat Themis Biosyn 45th AGM Approves Dividend, Fundraising
Gujarat Themis Biosyn held its 45th AGM on September 30, 2026, approving nine resolutions including dividend declaration and financial statements adoption.
Shareholders approved special business items
Themis Medicare 56th AGM Voting Results Approval
Themis Medicare Limited disclosed scrutinizer's report and voting results from its 56th Annual General Meeting held on September 30, 2026.
All five resolutions were approved with overwhelming majority
Aarti Drugs Chairman Retires; CFO Promoted to MD
Chairman & MD Prakash M. Patil ceased all roles effective Sept 30, 2026, due to early retirement.
CFO Adhish P. Patil relinquished his role, promoted to Managing Director effective October 1, 2026.
Th
Haleos Labs 20th AGM Approves 15% Dividend, Director Reappointments
Haleos Labs held its 20th AGM via video conference on September 30, 2026, transacting eight resolutions including financial approvals and director appointments.
Shareholders approved a 15% dividend fo
Anupam Rasayan Clarifies Bliss GVS Pharma Acquisition Details
Anupam Rasayan issues clarification correcting typographical errors in its previous disclosure regarding acquisition of Bliss GVS Pharma shares.
Confirms PAC acquired 5,09,84,595 equity shares represe
Aarey Drugs 36th AGM Approves Resolutions
Aarey Drugs held its 36th AGM on 30th September 2026, chaired by Mihir Ghatalia.
Members voted on three resolutions: financials adoption, director re-appointment, and related party transactions.
The m
Ind-Swift Laboratories 31st AGM Proceedings
Ind-Swift Laboratories held its 31st Annual General Meeting virtually on 30th September 2026, lasting 24 minutes with 47 shareholders present.
All four resolutions were passed, including adoption of f
Syncom Formulations 38th AGM Approves Dividend, Appointments
Syncom Formulations held its 38th AGM on 30th September 2026, approving a 10% dividend of ₹0.10 per share for FY2025-26.
Shareholders re-appointed Ankit Kedarmal Bankda and ratified appointments of Ra
Gujarat Themis Biosyn 45th AGM Proceedings
Gujarat Themis Biosyn held its 45th AGM on September 30, 2026, approving audited financial statements and declaring dividend for FY26.
Shareholders re-appointed Dr. Dinesh S. Patel as director and app
Natco Pharma 43rd AGM Approves ₹2000 Crore Fundraising
Natco Pharma held its 43rd Annual General Meeting on September 30, 2026, to vote on five resolutions including financial statements and dividend confirmation.
Shareholders approved a special resolutio
Medicamen Biotech Director Sells 32,813 Shares
Medicamen Biotech discloses Director Sanjay Bansal's sale of 32,813 equity shares via on-market transaction.
The transaction, valued at ₹1.05 crore, reduces Bansal's holding from 102,813 shares (0.76%
Lasa Supergenerics 11th AGM Proceedings September 2026
Lasa Supergenerics held its 11th Annual General Meeting via video conference on September 30, 2026, addressing seven resolutions.
The meeting covered adoption of accounts, director appointments, secre
Lincoln Pharma 32nd AGM Approves Dividend
Lincoln Pharmaceuticals held its 32nd Annual General Meeting on September 30, 2026, via video conference.
Shareholders approved a dividend of ₹1.80 per share and re-appointed two directors retiring by
Aarey Drugs Allots 11.5 Lakh Shares via Warrant Conversion
Board approved allotment of 11,50,000 equity shares upon conversion of warrants at ₹63.80 each, raising ₹5.50 crore.
Issued capital increased to ₹31.87 crore from ₹30.72 crore post this partial warran
Bhavna Grover Buys 25,000 Jeena Sikho Shares
Jeena Sikho Lifecare promoter Bhavna Grover purchased 25,000 equity shares via open market on September 29, 2026.
Her personal holding increased from 0.22% to 0.24% of the company's total voting capit
Symbiotec Pharmalab Q1 FY27 Earnings Call Highlights Growth
Symbiotec Pharmalab held its Q1 FY27 earnings call, providing a transcript as a regulatory disclosure per SEBI LODR regulations.
Management provided FY27 guidance targeting 20% revenue growth and 25%
9th Molecular Virology Meeting Concludes in New Delhi
The 9th Molecular Virology Meeting concluded at BRIC-NII, bringing together 200 clinicians and researchers to discuss viral biology and research translation.
The meeting featured research on influenza
India World's Largest Vaccine Producer by Volume
India is the world's largest vaccine producer by volume, supplying vaccines to over 100 countries and accounting for nearly 60% of global production.
India's bioeconomy reached USD 195.3 billion in 20
Sanofi India Promoter Group Acquires 15.2% Stake
Sanofi Healthcare India, a promoter group entity, purchased 3.5 million equity shares (15.20% stake) in Sanofi India Limited via a block deal.
The transaction was an inter-se transfer from promoter Ho
Sanofi India Promoter Hoechst Sells 3.5M Shares
Hoechst GmbH, a promoter of Sanofi India, sold 3.5 million equity shares via a block deal on NSE.
The shares were transferred inter-se to Sanofi Healthcare India Private Limited, another promoter grou
Evexia Lifecare Promoter Group Buys 5.03 Million Shares
Shree Saibaba Exim Private Limited, a promoter group entity, acquired 50,33,131 equity shares of Evexia Lifecare Limited via open market purchase on September 23, 2026.
The acquisition increases the p
Cupid Limited Projects ₹750 Crore FY27 Revenue
Cupid Limited reported FY26 revenue growth of 93% to ₹391 crore and PAT surge of 165% to ₹108 crore, exceeding initial guidance.
The company provided elevated FY27 guidance of ₹725-750 crore revenue a
Aarti Pharmalabs FY26 PAT Declines 31.5% YoY
Aarti Pharmalabs reported standalone FY26 PAT of ₹1,762 Mn, a 31.5% YoY decline due to forex losses and higher finance costs.
The company outlined a significant capex plan including ₹400 Cr Atali proj
Symbiotec Q1 FY26 Earnings Call Recording Available
Symbiotec Pharmalab Limited intimates availability of Q1 FY26 earnings conference call audio recording for investors and public.
The call, held on September 22, 2026, discussed operational and financi
Symbiotec Pharmalab Q1FY27 PAT Declines 53% YoY
Symbiotec Pharmalab reported Q1FY27 consolidated PAT of ₹14.1 crore, down 53% YoY from ₹29.9 crore, due to new business expenses.
API business grew 6% YoY with revenue of ₹215.3 crore and maintained ~
Symbiotec Pharmalab Q1FY27 Steady 6% Sales Growth
Symbiotec Pharmalab Limited disclosed its Q1FY27 unaudited results via an investor presentation following its September 2026 IPO, which raised Rs. 1,757 Cr.
Q1 sales grew 6% YoY with a 9% EBITDA growt
Essix Biosciences Acquires 70 Lakh Ind-Swift Warrants
Essix Biosciences Ltd acquired 70 lakh convertible warrants in Ind-Swift Laboratories Ltd on a preferential basis on September 17, 2026.
The acquisition increases the promoter & promoter group's total
Shree Saibaba Exim Purchases 3.76M Evexia Lifecare Shares
• Shree Saibaba Exim Private Limited, a Promoter Group entity, purchased 37,61,527 equity shares of Evexia Lifecare Limited on September 18, 2026.
• The acquisition, executed on the open market, incre
Evexia Lifecare Promoter Group Buys 20.7 Lakh Shares
Shree Saibaba Exim Private Limited, a promoter group entity, purchased 20,70,000 equity shares of Evexia Lifecare Limited on September 16, 2026.
The acquisition, executed on the BSE open market, incre
Deccan Health Care FY26 PAT Surges 91% Amid Regulatory Fines
Deccan Health Care reported FY26 standalone revenue growth of 18.7% to ₹891.71 crore and PAT surge of 91.2% to ₹22.90 crore, with consolidated PAT up 115% to ₹248.76 lakh.
The company issued 1.32 mill
Sangam Health Care FY26 Net Profit Falls 88% to ₹5.33 Lakh
Sangam Health Care submitted its FY25-26 annual report and AGM notice to BSE, disclosing an 88% YoY profit decline to ₹5.33 lakh on revenue of ₹11.23 crore.
The company seeks shareholder approval for
Novelix Pharmaceuticals 2025-26 Annual Report & AGM
Novelix Pharmaceuticals reported FY26 revenue of ₹132.31 crore and net profit of ₹2.56 crore, showing significant growth from previous year.
Company is holding 32nd AGM on September 30, 2026 to approv
Deep Health AI India Reports FY26 Revenue Growth to ₹4.25 Crore
Deep Health AI India reported FY26 revenue growth to ₹4.25 crore from ₹1.25 crore YoY with PAT of ₹1.29 crore and declared ₹1.44 crore dividend.
Company raised ₹39.97 crore via rights issue and signif
Amkay Products FY26 Revenue Up 9.5% to ₹4202.7 Lakh
Amkay Products Limited filed its 19th Annual General Meeting notice and Annual Report for FY 2025-26 with BSE, pursuant to SEBI Regulations 30 and 34.
Revenue from operations increased 9.47% to ₹4202.
Krebs Biochemicals Q1 FY2027 Net Loss ₹2.48 Crore
Board approved unaudited Q1 FY2027 financial results, reporting a net loss of ₹2.48 crore on revenue of ₹6.98 crore.
Manufacturing unit remains closed since Feb 2025 per Andhra Pradesh Pollution Contr
Novateor Research Laboratories FY26 Annual Report
Novateor Research Laboratories reported FY26 net profit of ₹10.12 lakhs versus FY25 loss of ₹8.18 lakhs with total income of ₹382.75 lakhs.
The company converted 12.18 lakh equity warrants, increasing
Achyut Healthcare 31st AGM Notice and Annual Report
Achyut Healthcare Limited submitted its 31st Annual Report to BSE under SEBI Regulation 34, containing audited financial statements for FY 2025-26.
The company reported revenue of ₹1197.15 lakhs (up f
Titan Biotech FY26 Profit Rises 33% with Bonus Dividend
Titan Biotech reported consolidated net profit of ₹298.85 crore for FY26, up 33% from previous year, with revenue growing 32% to ₹206.19 crore.
The Board recommended a dividend of ₹0.50 per share and
Roopa Industries 41st AGM Notice and FY26 Results
Roopa Industries Limited submitted its 41st Annual Report for FY 2025-26 and notice of AGM scheduled for September 30, 2026, to be held via video conference.
The company reported a significant decline
Bilcare Limited FY26 Results: AGM Approves Director Changes
Bilcare reported consolidated net profit of ₹172.84 lacs for FY26, reversing from a ₹78.36 lacs loss in FY25, despite standalone revenue declining to ₹6.85 crore.
The Board modified Executive Director
Norris Medicines 35th Annual Report FY26 Submission
Norris Medicines submitted its 35th Annual Report for FY 2025-26 to BSE, reporting a reduced net loss of ₹28.06 lakhs on revenue of ₹813.20 lakhs.
The AGM notice includes special resolutions to appoin
Norris Medicines 35th AGM Notice FY2025-26
Norris Medicines schedules its 35th AGM for 29th September 2026 via VC/OAVM to adopt FY2026 financials and consider special resolutions.
Company reports reduced net loss of ₹28.06 lakhs on revenue of
Anupam Rasayan Bliss GVS Open Offer 1,669 Shares Acquired
Anupam Rasayan India Limited's open offer for 26% of Bliss GVS Pharma concluded with only 1,669 shares tendered and accepted, a tiny fraction of the 2.77 crore shares offered.
The acquirer paid ₹299 p
Mihir Shah Acquires 3.77 Lakh Parnax Lab Shares via Gift
Mihir Shah, a promoter of Parnax Lab, acquired 377,355 equity shares from fellow promoter Baiju Shah via inter-se gift transfer on July 21, 2026.
The transaction falls under SEBI Takeover Regulations
Colinz Laboratories Open Offer for 26% at ₹54/share
Saffron Capital issued a reminder advertisement for an open offer by Annjana Dugar, Likhitta Dugar, and Antariksh Dugar with PAC Padam Dugar to acquire 654,966 shares (26%) of Colinz Laboratories at ₹
Anuh Pharma Promoters Withdraw Reclassification Request
Anuh Pharma Ltd discloses withdrawal of application to reclassify three promoter group members from 'Promoter' to 'Public' category.
Vikram Kirtilal Shah, Kiran Piyush Shah, and Kinjal Siddharth Jhave
Hester Biosciences Promoters Reclassified to Public Category
Hester Biosciences intimates BSE and NSE of promoter reclassification approval under SEBI LODR Regulation 31A.
NSE and BSE grant no-objection for Ravin Gandhi and Bela Gandhi's move from Promoter Grou
Panacea Biotec Promoter Gift Transfer to HUF
Dr. Rajesh Jain transfers 200,000 Panacea Biotec shares via gift to his HUF, claiming SEBI takeover regulation exemption.
The transaction was executed at zero consideration on June 12, 2026, with SEBI